

ARTICLE

Factor XII-driven coagulation traps bacterial infections

Katrin F. Nickel^{1,2}, Anne Jämsä³, Sandra Konrath¹, Praveen Papareddy⁴, Lynn M. Butler^{2,5,6}, Evi X. Stavrou^{7,8}, Maike Frye^{1,9}, Mathias Gelderblom¹⁰, Bernhard Nieswandt^{11,12}, Sven Hammerschmidt¹³, Heiko Herwaldt⁴, and Thomas Renné^{1,14,15}

Blood coagulation is essential for stopping bleeding but also drives thromboembolic disorders. Factor XII (FXII)-triggered coagulation promotes thrombosis while being dispensable for hemostasis, making it a potential anticoagulant target. However, its physiological role remains unclear. Here, we demonstrate that FXII-driven coagulation enhances innate immunity by trapping pathogens and restricting bacterial infection in mice. *Streptococcus pneumoniae* infection was more severe in FXII-deficient (*F12*^{−/−}) mice, with increased pulmonary bacterial burden, systemic spread, and mortality. Similarly, *Staphylococcus aureus* skin infections and systemic dissemination were exacerbated in *F12*^{−/−} mice. Reconstitution with human FXII restored bacterial containment. Plasma kallikrein amplifies FXII activation, and its deficiency aggravated *S. aureus* skin infections, similarly to *F12*^{−/−} mice. FXII deficiency impaired fibrin deposition in abscess walls, leading to leaky capsules and bacterial escape. Bacterial long-chain polyphosphate activated FXII, triggering fibrin formation. Deficiency in FXII substrate factor XI or FXII/factor XI co-deficiency similarly exacerbated *S. aureus* infection. The data reveal a protective role for FXII-driven coagulation in host defense, urging caution in developing therapeutic strategies targeting this pathway.

Introduction

The blood coagulation system consists of a group of tightly regulated plasma proteases, leading to the production of fibrin, which stops bleeding at sites of vascular injury (hemostasis). However, fibrin is also a key component of thrombi that occlude blood vessels and underlie thromboembolic diseases such as ischemic stroke, myocardial infarction, and pulmonary embolism—together representing the leading causes of death in the developed world (Townsend et al., 2022). Fibrin formation can be initiated by two distinct mechanisms, triggered by either exposure of blood to a damaged vessel wall (extrinsic pathway) or by blood-borne factors (intrinsic pathway). The intrinsic pathway of coagulation begins when factor XII (FXII) binds to anionic surfaces, triggering its conversion to the enzymatically active form, FXIIa. In the classical cascade model, FXIIa drives fibrin production via its substrate, factor XI (FXI). Alternatively, FXI can be activated by FXII-independent mechanisms (“feedback activation”).

FXII-driven coagulation was first recognized as essential for surface-activated diagnostic blood coagulation assays (e.g., the activated partial thromboplastin time), which are commonly used as a clinical measure of global plasma coagulation. Despite its critical role in fibrin production in the test tube, for decades FXII was thought to have no function in coagulation in vivo (Long et al., 2016). This premise was based on the fact that individuals deficient in FXII have a normal hemostatic capacity and do not exhibit increased bleeding. Unexpectedly and challenging the dogma of the coagulation balance, “pathological” fibrin formation, and thrombosis were defective in animal models of hereditary FXII deficiency (Renné et al., 2005). FXII-deficient mice were protected in models of thromboembolic diseases, such as ischemic stroke (Kleinschnitz et al., 2006), deep vein thrombosis (DVT), and pulmonary embolism (Grover et al., 2020; Meng et al., 2021).

¹Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ²Clinical Chemistry, Department of Molecular Medicine and Surgery, and Center of Molecular Medicine, Karolinska Institutet and University Hospital, Stockholm, Sweden; ³Clinical Chemistry, Medical Diagnostics, Karolinska University Hospital, Stockholm, Sweden; ⁴Department of Laboratory Medicine, Biomedical Center (BMC), Lund University, Lund, Sweden; ⁵Department of Clinical Medicine, The Arctic University of Norway, Tromsø, Norway; ⁶Science for Life Laboratory, Department of Protein Science, Royal Institute of Technology (KTH), Stockholm, Sweden; ⁷Medicine Service, Section of Hematology-Oncology, Louis Stokes Veterans Administration Medical Center, Cleveland, OH, USA; ⁸Department of Medicine, Hematology and Oncology Division, Case Western Reserve University School of Medicine, Cleveland, OH, USA; ⁹German Centre of Cardiovascular Research (DZHK), Partner Site Hamburg/Luebeck/Kiel, Hamburg, Germany; ¹⁰Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ¹¹Institute of Experimental Biomedicine, Chair of Experimental Biomedicine I, University Hospital Würzburg, Würzburg, Germany; ¹²Rudolf Virchow Center for Integrative and Translational Bioimaging, Julius-Maximilians-Universität Würzburg, Würzburg, Germany; ¹³Department of Molecular Genetics and Infection Biology, Interfaculty Institute of Genetics and Functional Genomics, Center for Functional Genomics of Microbes, University of Greifswald, Greifswald, Germany; ¹⁴Center for Thrombosis and Hemostasis (CTH), Johannes Gutenberg University Medical Center, Mainz, Germany; ¹⁵Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.

Correspondence to Thomas Renné: thomas@renne.net.

© 2025 Nickel et al. This article is available under a Creative Commons License (Attribution 4.0 International, as described at <https://creativecommons.org/licenses/by/4.0/>).

Based on the critical role of FXII in thrombosis while sparing hemostasis, the protease has emerged as a promising target for safer anticoagulant drug development (Kalinin, 2021). FXII(a)-blocking antibodies (Larsson et al., 2014; Xu et al., 2024), cyclic peptide inhibitors (Wilbs et al., 2020), knockdown of FXII expression by antisense oligonucleotides (ASO) and small interfering RNAs have been developed and shown to provide thromboprotection without bleeding risk in mouse and large animal models of thrombosis (Liu et al., 2020; Revenko et al., 2011; Umei et al., 2023; Yau et al., 2014). However, despite the pathological function of FXII in thrombosis, deficiency in the protease is rare in humans, suggesting that FXII-triggered coagulation may have an important physiological function.

Polyphosphate (polyP) is a linear polymer consisting of two to several thousand orthophosphate units connected by energy-rich phosphoanhydride bonds. In bacteria, polyP serves as a phosphate reservoir and energy storage (Müller et al., 2019). In mammalian blood, extracellular polyP triggers procoagulant responses, including the activation of FXII through contact, acceleration of factor V activation, disruption of fibrinolysis, interference with the anticoagulant function of tissue factor (TF) pathway inhibitors (TFPIs), and a significant amplification of FXI feedback activation (Müller et al., 2009; Morrissey and Smith, 2015; Mailer et al., 2019).

PolyP-activated FXII cleaves plasma prekallikrein (PK) to generate active plasma kallikrein (PKa), which in turn reciprocally activates additional FXII molecules. The amplification loop culminates in a burst of FXIIa activity. Conversely, deficiencies in FXII or PK impair or largely delay contact-induced coagulation (Kearney et al., 2024).

In addition to coagulation, FXIIa activates the bradykinin-producing proinflammatory kallikrein-kinin system (reviewed by Nickel and Renné [2012]). Experimental and clinical data have linked FXIIa and the kallikrein-kinin system to bacterial infections (Herwald et al., 1998; Isenring et al., 2018; Kahn et al., 2002; Sriskandan et al., 2000; Wuillemin et al., 1995).

Gram-positive *Staphylococcus aureus* (*S. aureus*) and *Streptococcus pneumoniae* (*S. pneumoniae*) infections present a major clinical burden. *S. aureus* is one of the most common causes of skin and soft tissue infections and endocarditis (Lowy, 1998), while *S. pneumoniae* (the pneumococcus) is a leading cause of upper and lower respiratory tract infections. Both *S. aureus* and pneumococcal infections are associated with activated coagulation, and upregulated expression of certain coagulation factors (i.e., acute phase response) is a hallmark of bacterial infection. Abscess walls with fibrin deposits are typical of staphylococcal and streptococcal infections and contribute to bacterial trapping and host defense (Cheng et al., 2011; Kobayashi et al., 2015).

Here, we investigated pneumococcal lung and staphylococcal skin infections in mice deficient in FXII-initiated procoagulant pathways. Our findings demonstrate that deficiency in FXII-driven coagulation enhances bacterial infection severity and dissemination. In contrast, fibrin formation mediated by the polyP-FXII-FXI axis supports abscess wall integrity and facilitates bacterial entrapment. These results reveal a physiological role for FXII-driven coagulation in innate immune defense against bacterial pathogens.

Results


Increased *S. pneumoniae* dissemination and pneumonia lethality in FXII-deficient mice

To investigate the role of FXII in host defense, we used a lethal pneumonia model driven by intranasal inoculation of FXII-deficient (*FXII*^{-/-}) and WT mice with bioluminescent *S. pneumoniae* (strain Xen10, a serotype 3 derivative of strain A66). In vivo bioluminescence correlates closely with bacterial CFUs (Miller et al., 2006). Bacterial growth was accelerated in *FXII*^{-/-} mice compared with WT controls, resulting in a higher bacterial burden in challenged lungs ($6.8 \pm 1.0 \times 10^6$ versus $2.3 \pm 0.8 \times 10^6$ photons/sec on day 3, $P < 0.01$; Fig. 1, A and B). Consistent with a more severe lung infection, bacterial load was significantly higher both in lung tissues ($111 \pm 32 \times 10^5$ versus $37 \pm 12 \times 10^5$ CFU; $P < 0.05$ versus WT; Fig. 1 C) and bronchoalveolar lavage fluid ($288 \pm 90 \times 10^4$ versus $85 \pm 27 \times 10^4$ CFU; $P < 0.05$ versus WT; Fig. 1 D) of challenged *FXII*^{-/-} mice compared with WT controls. In all WT mice (15 of 15), bioluminescence signals remained restricted to the primary site of infection, the lung. In contrast, pneumococci disseminated in *FXII*^{-/-} mice, with bioluminescence signals detected at peripheral sites beyond the lungs in 6 out of 15 challenged mice (Fig. 1 E). Dissemination of pneumococci was associated with significantly higher lethality. At 82 h after infection, 22 of 24 *FXII*^{-/-} mice had died, whereas only 14 of 24 WT mice succumbed during this period ($P < 0.05$ versus WT; Fig. 1 F).

Increased *S. aureus* skin infection and bacterial dissemination in FXII-deficient mice

To demonstrate that FXII deficiency confers an increased risk of bacterial infection severity and pathogen dissemination, we challenged WT and *FXII*^{-/-} mice in a skin infection model by subcutaneously inoculating animals with bioluminescent *S. aureus* (Malachowa et al., 2013). In WT animals, infections progressed but peaked by day 2 after challenge, after which bacterial bioluminescence signals decreased. In contrast, bacterial loads reached significantly higher levels in *FXII*^{-/-} animals ($10.4 \pm 0.8 \times 10^7$ versus $4.5 \pm 1.1 \times 10^7$ photons/sec for *FXII*^{-/-} versus WT animals at day 2, $P < 0.001$) and remained nearly constant after day 2, resulting in greater than fivefold higher bacterial counts at day 5 compared with WT mice ($1.3 \pm 0.3 \times 10^7$ versus $6.2 \pm 1.8 \times 10^7$, $P < 0.05$; Fig. 2, A and B). Consistent with bioluminescent signal intensities, macroscopic skin wounds developed more rapidly and were significantly larger in *FXII*^{-/-} mice compared with WT controls (7.6 ± 0.8 versus 4.3 ± 0.6 cm² at day 5, $P < 0.01$ versus WT; Fig. 2 C).

To test whether human FXII has a similar importance in entrapping infections as the mouse homolog and to confirm that the increased infection severity observed in *FXII*^{-/-} animals was specifically due to absence of FXII and not a secondary effect of the deficiency state, we reconstituted *FXII*^{-/-} mice with human FXII (2 µg/g body weight) to normal plasma levels (Kleinschnitz et al., 2006). Reconstitution normalized the prolonged plasma-activated partial thromboplastin time (a measure of FXII-driven coagulation) in *FXII*^{-/-} mice (from 69 ± 15 to 30 ± 5 sec), bringing it close to WT levels (28 ± 4 sec, $P > 0.05$ versus *FXII*^{-/-} + FXII). *S. aureus* infections in human FXII-reconstituted *FXII*^{-/-} mice developed similarly to those in WT mice ($2.0 \pm 0.4 \times 10^7$ photons/sec at day 5, $P > 0.05$ versus



WT; right panels in Fig. 2, A and B), and the maximum lesion size was comparable with WT controls (5.2 ± 0.5 cm² at day 5, $P > 0.05$ versus WT; Fig. 2 C).

The high local primary *S. aureus* skin infections facilitate systemic spread of the pathogen (Howden et al., 2023). Therefore, we analyzed mice for bacterial dissemination to peripheral sites. The bacterial load in kidneys (610 ± 285 in *F12*^{-/-} versus 10 ± 5 in WT and 45 ± 26 CFU in *F12*^{-/-} + FXII at day 5, $P < 0.05$ versus WT), spleens ($1,218 \pm 535$ versus 17 ± 11 and 51 ± 30 CFU, $P < 0.05$), lungs (682 ± 332 versus 5 ± 2 and 45 ± 26 CFU, $P < 0.05$), and livers (441 ± 199 versus 14 ± 9 and 21 ± 13 CFU, $P <$

0.05) was significantly increased in *F12*^{-/-} mice compared with WT mice. In contrast, *S. aureus* disseminated to a similar range in FXII-reconstituted *F12*^{-/-} and WT mice, with bacterial counts equally low in all tested organs (FXII versus WT $P > 0.05$; Fig. 2, D–G).

Increased *S. aureus* infection and dissemination in PK-deficient mice

The activation of FXII is dependent on PKa, and conversely, PK deficiency impairs FXIIa formation (Kearney et al., 2024). We investigated the effects of PK deficiency (kallikrein B1 gene





Figure 2. Accelerated *S. aureus*-induced skin infection in FXII-deficient mice is rescued by human FXII. WT, F12^{-/-} mice, and F12^{-/-} mice reconstituted once with a dose of 2 μ g human FXII per gram of body weight (F12^{-/-}+FXII) were injected subcutaneously with 1×10^9 CFU *S. aureus* bioluminescent strain Xen29 ($n = 10$ per group). **(A)** Representative *S. aureus* in vivo bioluminescence on a pseudocolor scale overlaid on top of a greyscale image of WT, F12^{-/-}, and F12^{-/-}+FXII mice. **(B)** Bacterial counts as measured by in vivo bioluminescence of *S. aureus* demonstrated as mean total flux (photons per second) in a logarithmic scale. **(C)** Mean total size of the skin lesion in cm² $\pm$ SEM. **(D–G)** Bacterial burdens observed in kidneys (D), spleens (E), lungs (F), and livers (G) of WT, F12^{-/-}, and F12^{-/-}+FXII mice at day 5 after infection. Values are CFUs $\pm$ SEM within the entire organ as determined by serial dilutions of tissue homogenates. * $P < 0.05$ and ** $P < 0.01$ versus WT (B and C) or F12^{-/-} (D–G). P values were determined using Student's t test (B and C) or one-way ANOVA (D–G).

[*Klkb1*]^{-/-} mice; Sala-Cunill et al., 2015) in our model of *S. aureus*-mediated skin infection. Bacterial bioluminescence signals at the infection site in *Klkb1*^{-/-} mice were significantly elevated compared with WT animals ($8.9 \pm 2.0 \times 10^7$ versus $2.9 \pm 1.0 \times 10^7$ photons/sec at day 2; $P < 0.05$ versus WT). While bioluminescence in *Klkb1*^{-/-} mice plateaued on day 3, bacterial burden decreased in WT animals. By day 5 after infection,

bacterial load in *Klkb1*^{-/-} mice was over 10-times higher than in WT animals ($22.6 \pm 9.0 \times 10^7$ versus $1.8 \pm 0.8 \times 10^7$ photons/sec, $P < 0.05$ versus *Klkb1*^{-/-}, Fig. 3, A and B). The increased bacterial burden in *Klkb1*^{-/-} mice resulted in more rapid lesion development, with lesion sizes exceeding those in WT mice by more than twofold (8.7 ± 1.2 versus 3.9 ± 0.7 cm² at day 5, $P < 0.01$ versus WT, Fig. 3 C). There were no statistically significant



differences in bioluminescence or lesion size between *Klkb1*^{-/-} and *F12*^{-/-} mice. Bacterial spread to peripheral organs was markedly increased in *Klkb1*^{-/-} mice compared with WT animals, as evidenced by significantly higher bacterial burdens in kidneys (429 ± 181 versus 38 ± 25 CFU, $P < 0.05$ versus WT, Fig. 3 D), spleens (375 ± 167 versus 22 ± 15 CFU, $P < 0.05$ versus WT, Fig. 3 E), lungs (352 ± 117 versus 18 ± 14 CFU, $P < 0.05$ versus WT, Fig. 3 F), and livers (203 ± 98 versus 27 ± 16 CFU, $P < 0.05$ versus WT, Fig. 3 G). The extent of bacterial dissemination in *Klkb1*^{-/-} mice was comparable with that observed in *F12*^{-/-} mice (dashed lines indicate mean bacteria load observed in *F12*^{-/-} mice, $P >$

0.05; *Klkb1*^{-/-} versus *F12*^{-/-}). In summary, deficiencies in FXII and PK promote increased *S. aureus* and *S. pneumoniae* growth at the primary infection site and significantly enhance bacterial dissemination to peripheral organs.

Defective formation of a fibrin abscess capsule facilitates bacterial spreading

Fibrous abscess formation is a hallmark of *S. aureus* skin infections (Kobayashi et al., 2015). A fibrin-rich pseudocapsule functions to trap bacteria and prevents the dissemination of the pathogen (Cheng et al., 2011). FXII has the ability to initiate

fibrin formation in pathological thrombosis; conversely, thrombus formation is impaired in *FXII*^{-/-} mice (Renné et al., 2005). We hypothesized that FXII-driven prothrombotic mechanisms may also contribute to the formation of an abscess wall. To test this hypothesis, skin abscesses of *S. aureus*-infected *FXII*^{-/-} and WT mice were histologically compared (Fig. 4, A–H).

In H&E-stained sections of WT mice wounds, a distinct layer of amorphous pinkish material was identified that surrounded bacteria within the abscess core (Fig. 4, A and C). In contrast, this abscess capsule was less defined in *FXII*^{-/-} animals (Fig. 4, B and D). To verify the composition and relative quantities of the amorphous material in the abscess wall, we used the antibody 59D8 that specifically binds to fibrin following thrombin-mediated cleavage of fibrinogen and lacks cross-reactivity with the precursor protein (Kleinschnitz et al., 2006). 59D8 immunohistochemistry demonstrated the presence of fibrin deposits along the margins of the *S. aureus* abscess capsules in both WT and *FXII*^{-/-} mice (Fig. 4, E–H). In comparison to the levels observed in WT animals (which were set to 100 ± 4%), the total fibrin content within the abscess wall was reduced by half (50 ± 3%) in *FXII*^{-/-} mice, as determined from the 59D8 immunohistochemical signal intensities (Fig. 4 I).

Consistent with the reduced fibrin deposition observed in the abscess capsule, the overall gap size in the abscess wall, as assessed from histological images was increased by more than threefold in *FXII*^{-/-} mice compared with WT animals (Fig. 4 J). Defective capsule integrity permitted the spread of *S. aureus* through the abscess wall into surrounding tissues in *FXII*^{-/-} mice, whereas virtually no bacteria were detectable outside the abscess capsule in WT animals (45.0 ± 7.0 versus 1.0 ± 0.5 per high-power field in *FXII*^{-/-} versus WT; Fig. 4 K).

We further investigated the mechanism underlying the initiation of fibrin formation in *S. aureus*-associated abscess capsules. Bacteria contain polyP, which functions as their energy storage pool. We hypothesized that bacterial polyP induces FXII contact activation and triggers FXII/PK-mediated coagulation in plasma. Negative DAPI staining revealed that *S. aureus* contained long-chain polyP with chain length of 400 to >1,000 phosphate monomers. The DAPI-negative signal was susceptible to incubations with recombinant exopolyphosphatase (PPX), an enzyme that specifically cleaves polyP with a chain length greater than >35 phosphate units (Rangarajan et al., 2006), confirming that loaded material purified from bacteria was polyP. Synthetic long-chain polyP was treated identically and loaded as control (Fig. 4 L). *S. aureus*-derived polyP triggered coagulation in normal plasma (Fig. 4 M). In contrast, *S. aureus*-derived polyP was inactive for triggering thrombin production in plasma that is deficient in FXII or the FXIIa substrate FXI. Similarly, thrombin generation in normal plasma was largely reduced when bacterial polyP was preincubated with the recombinant polyP-neutralization probe PPX_{Δ12} (Labberton et al., 2016). We analyzed whether the polyP-FXII axis contributes to *S. aureus*-mediated coagulation under more physiological settings in the presence of blood flow. Citrate anticoagulated whole blood was recalcified and then perfused over immobilized *S. aureus* (Fig. 4 N). When WT mouse blood was perfused over *S. aureus* bacteria, thrombi formed within 7 min from the time of

perfusion (37 ± 8% surface covered area). In contrast, deficiency in FXII or FXI or addition of the polyP inhibitor PPX_{Δ12} largely reduced *S. aureus*-driven thrombus formation to 8 ± 3%, 4 ± 3%, and 7 ± 2%, respectively. Taken together, the data show that *S. aureus* polyP has the capacity to initiate coagulation via the polyP-FXII axis in plasma.

The FXII–FXI pathway contributes to abscess wall integrity in *S. aureus* infections

PolyP initiates procoagulant activity in vitro by two alternative mechanisms: (1) by amplifying activated FXI-mediated TFPI inactivation (Puy et al., 2016) and (2) by inducing FXII contact activation leading to FXI activation (Müller et al., 2009). To identify the mechanism by which FXII mitigates *S. aureus* skin infection severity and pathogen dissemination, we used FXI-deficient (*FXI*^{-/-}) and *FXII*^{-/-}/*FXI*^{-/-} double gene-deficient mice (Müller et al., 2009). If fibrin production for *S. aureus* encapsulation is mediated by FXII activation and the subsequent activation of FXI by FXIIa, then *FXI*^{-/-} and *FXII*^{-/-}/*FXI*^{-/-} animals should be susceptible to *S. aureus* infections to the same extent as *FXII*^{-/-} mice. Indeed, skin infection sites were significantly increased in *FXI*^{-/-} and *FXII*^{-/-}/*FXI*^{-/-} mice compared with WT animals starting from day 2 and only slightly decreased until day 5 after challenge (2.7 ± 0.5 × 10⁷ and 3.5 ± 1.0 × 10⁷ versus 1.0 ± 0.3 × 10⁷ photons/sec, P < 0.05 versus WT; Fig. 5, A and B). Bacterial bioluminescence signals were similar in *FXI*^{-/-} and *FXII*^{-/-}/*FXI*^{-/-} mice and not different from infected *FXII*^{-/-} animals (P > 0.05 for all comparisons). Skin lesions developed faster and with similar kinetics in infected *FXI*^{-/-} and *FXII*^{-/-}/*FXI*^{-/-} compared with WT mice (8.1 ± 1.0 and 7.5 ± 0.8 cm² versus 4.6 ± 0.7 cm², P < 0.05 versus WT). Skin ulcers in *FXI*^{-/-} and *FXII*^{-/-}/*FXI*^{-/-} animals were not significantly different in size from those observed in *FXII*^{-/-} mice (P > 0.05 each; Fig. 5 C). Increased bacterial growth at the injection site was associated with increased bacterial burden, dissemination rates, and severity of infection. Bacterial loads in *FXI*^{-/-} and *FXII*^{-/-}/*FXI*^{-/-} mice were significantly higher than those in WT animals in kidneys (879 ± 412, 318 ± 156 versus 9 ± 5 CFU, P < 0.05 versus WT, Fig. 5 D), spleens (603 ± 284, 293 ± 103 versus 6 ± 3 CFU, P < 0.05 versus WT, Fig. 5 E), lungs (501 ± 222, 375 ± 126 versus 12 ± 8 CFU, P < 0.05 versus WT, Fig. 5 F), and livers (478 ± 219, 541 ± 248 versus 14 ± 9 CFU, P < 0.05 versus WT, Fig. 5 G). In all tissues analyzed, bacterial load was similar in *FXI*^{-/-} and *FXII*^{-/-}/*FXI*^{-/-} mice and comparable with that in *FXII*^{-/-} mice (indicated by dashed lines in Fig. 5, D–G).

Discussion

The innate immune system represents a phylogenetically ancient strategy that provides the first line of defense against invading pathogens. In invertebrates with an open circulatory system, such as arthropods and mollusks, a hemolymph coagulation system captures pathogens, preventing them from entering the host. This ancient cross talk between innate immunity and coagulation is thought to have persisted through evolution (Loof et al., 2011; van der Poll and Herwaldt, 2014). Experimental and preclinical studies have identified a pivotal role of the FXII–FXI-driven coagulation pathway in pathologic thrombosis




Figure 4. Defective *S. aureus* polyP-mediated fibrin formation and impaired fibrous abscess capsule integrity in *F12*^{-/-} mice. (A–H) WT, *F12*^{-/-} mice were subcutaneously inoculated with 3×10^6 CFU *S. aureus*, and abscesses were removed 30 h after infection. Representative photographs of skin sections stained with (A–D) H&E or (E–H) fibrin-specific antibody 59D8 are shown. Dashed lines and black arrows denote abscess capsule and fibrin staining around the abscess, respectively. Scale bars represent 50 μ m. (I) Quantification of fibrin staining given in % relative to WT mice. (J) Integrity of abscess capsule measured from immunohistochemistry sections by gaps within the discontinuous fibrin layer of the abscess capsule given relative to the abscess perimeter. (K) Number of *S. aureus* detected in the peripheral zone of the abscess given in relative to bacteria counts detected in WT mice, set to 100%. Images were analyzed with ImageJ software. Each symbol represents an individual animal. (L) PolyP was extracted from *S. aureus* by anion exchange chromatography, separated on polyacrylamide/urea gel and visualized by DAPI-negative staining. Synthetic polyP with mean chain lengths of 39, 97, and 383 phosphate monomers served as molecular size standard. Purified polyP was loaded without and after incubation with PPX (10 U/ml for 2 h). A representative gel of $n = 3$ is shown. (M) Real-time thrombin generation in normal human plasma stimulated with *S. aureus*-derived polyP in the absence or presence of PPX Δ 12 (1 mg/ml). Plasma deficient in FXII (FXII def.) or FXI (FXI def.) and buffer-stimulated normal plasma was blotted for comparison. Representative thrombin generation curves of a series of $n = 3$. (N) Citrated whole mouse blood, readjusted to physiological Ca^{2+} and Mg^{2+} concentrations, was perfused over a surface coated with 3×10^6 CFU *S. aureus* at a venous (100 s⁻¹) shear rate. Representative phase-contrast images of thrombi formed during perfusion of WT, *F12*^{-/-}, *F11*^{-/-}, or PPX Δ 12-treated WT blood are shown. Surface covered area by all thrombi in % is given in the lower right corner. A representative experiment of $n = 3$ is shown. Source data are available for this figure: SourceData F4.




Figure 5. FXII-FXI-driven coagulation traps *S. aureus* in skin infection. (A) WT, F11^{-/-}, or F12^{-/-}/F11^{-/-} mice were injected subcutaneously with 1×10^9 CFU *S. aureus* bioluminescent strain Xen29 ($n = 10$ per group). Representative *S. aureus* in vivo bioluminescence on a pseudocolor scale overlaid on top of a greyscale image of WT, F11^{-/-}, or F12^{-/-}/F11^{-/-} mice are shown. (B) Bacterial counts as measured by in vivo bioluminescence of *S. aureus* demonstrated as mean total flux (photons per second) $\pm$ SEM in a logarithmic scale. (C) Mean total size of the skin lesion in cm² $\pm$ SEM. * $P < 0.05$, ** $P < 0.01$ F11^{-/-} versus WT mice and * $P < 0.05$, *** $P < 0.01$ F12^{-/-}/F11^{-/-} versus WT mice in A. (D–G) Bacterial burden observed in kidneys (D), spleens (E), lungs (F), and livers (G) of WT, F11^{-/-}, and F12^{-/-}/F11^{-/-} mice compared with F12^{-/-} mice (dashed lines) at day 5 after infection. Values are CFUs $\pm$ SEM within the entire organ as determined by serial dilutions of tissue homogenates. * $P < 0.05$ versus WT mice. P values were determined using Student's *t* test.

but not hemostasis (Chan and Weitz, 2023; Kluge et al., 2022; Müller et al., 2011). The present study shows that coagulation mechanisms underlying pathologic thrombosis may have beneficial functions in host defense by contributing to fibrin abscess capsules formation, thereby limiting bacterial dissemination. Accordingly, deficiency in the FXII-FXI axis impairs contact-driven coagulation and increases the spreading of Gram-positive pneumococci and *S. aureus* (Figs. 1,2, and 5).

Consistent with our data from mouse models, *S. aureus* induces thrombin generation in human plasma via activation of FXII (Loof et al., 2015; Mattsson et al., 2001). Multiple clinical studies have shown that FXII is activated and consumed in plasma during Gram-negative sepsis (Duan et al., 2023; Levi et al., 2003; Wuillemin et al., 1995). Furthermore, FXII activation is associated with poor prognosis in infected patients with overt disseminated intravascular coagulation (DIC) (Park et al.,

2016). Although it is difficult to conclude from case reports, the medical history of Mr. John Hageman, the index patient for FXII deficiency, supports a role for FXII in host defense. Mr. Hageman had a lifelong history of recurrent sinusitis that is commonly caused by *S. aureus* infections (Ratnoff, 1980).

Consequences of FXII-FXI-driven coagulation in bacterial infections depend on the localization of coagulation activation. At primary sites of infection in the skin (Figs. 2 and 5) and lung (Fig. 1), fibrin production mediated by the FXII-FXI axis provides protection by fibrous abscess capsule wall formation. In contrast, once the pathogen has entered the circulation, FXII-FXI-driven coagulation becomes detrimental. Procoagulant reactions triggered by disseminated bacteria in the blood stream contribute to DIC. Indeed, intravenous infusion of heat-inactivated *S. aureus* (Silasi et al., 2021) or live *Escherichia coli* (Jansen et al., 1996; Pixley et al., 1993) induces severe thrombo-inflammatory responses in an FXII-dependent manner in non-human primates. Infection severity was consistently increased in our *F11*^{-/-} and *F12*^{-/-}/*F11*^{-/-} mice following intravenous administration of live *S. aureus* (data not shown). Conversely, targeting FXII in the circulation with inhibitory antibodies improves survival (Pixley et al., 1993). Similarly, infusion of FXI-neutralizing antibodies improves survival following polymicrobial peritoneal sepsis induced by cecal ligation and puncture (Tucker et al., 2012). Taken together, FXII-FXI-driven coagulation contributes to the entrapment of these two Gram-positive cocci at the site of infection. The procoagulant mediator polyP has been detected in a wide range of bacterial species, including *S. aureus*, the SL-1 *Streptococcus* strain, and *S. pneumoniae*, with levels reaching up to 30% of bacterial dry weight in *Acinetobacter johnsonii* (Tanzer and Krichevsky, 1970; Deinema et al., 1985; Kulaev and Vagabov, 1983; Bowlin and Gray, 2021). The polymer's chain length and content are subject to dynamic regulation by activities of polyP kinases PPK1 and PPK2, and PPX, the phosphate regulon, and responses to environmental stresses (Lamarche et al., 2008). Adding to this complexity, platelets and other blood-circulating cells release polyP (Müller et al., 2009; Moreno-Sanchez et al., 2012; Verhoef et al., 2017), while polymers from disintegrating host lung and skin cells may also contribute to FXII contact activation (Kumble and Kornberg, 1995). Furthermore, FXI can be activated independently of FXII via TF-triggered thrombin, which is further amplified by polyP (Choi et al., 2011), suggesting a complex role for polyP in FXII-FXI and TF-thrombin-FXI pathways involved in bacterial containment. However, if bacteria escape and enter the circulation, the coagulation pathway can go awry, culminating in DIC.

To escape coagulation-based entrapment in a host, bacteria express plasminogen activators (Pla's), which have been shown to support pathogen dissemination (McDevitt et al., 1997; Sun et al., 2004). In particular, the plague agent *Yersinia pestis* has the ability to disrupt clots by activating the host fibrinolytic system (Sun et al., 2004). *Yersinia* species express a surface Pla that facilitates bacterial dissemination. Targeting Pla, however, results in effective control of the infection, an increased presence of inflammatory cells at the infection sites, and significantly improved survival rates. Other pathogens,

including pneumococci and *S. aureus* express enzymes that activate the host fibrinolytic system (Wang et al., 1998), disrupt the integrity of the abscess wall, and enable *S. aureus* dissemination in skin infection models (Bergmann and Hammerschmidt, 2007; Peetermans et al., 2014).

Consistent with natural bacterial polyP (Fig. 4), synthetic polyP of the size produced by bacterial triggers FXII-dependent coagulation (Zilberman-Rudenko et al., 2018). In addition to driving coagulation by activating host FXII, *S. aureus* has the ability to induce fibrin production via its endogenous coagulases staphylocoagulase and von Willebrand factor-binding protein. These bacterial proteins exert procoagulant activity via direct activation of prothrombin that in turn leads to the formation of a staphylothrombin complex. Staphylothrombin converts fibrinogen into fibrin (Friedrich et al., 2003), driving fibrous abscess capsule formation (McAdow et al., 2012). Formation of fibrin by staphylothrombin provides an explanation for residual fibrin deposits in FXII-deficient mice (Fig. 4, F and H). The relative importance of FXII-FXI and staphylocoagulase pathways appears to depend on the site of infection, bacterial strain, and phase of infection. In a rabbit skin and soft tissue infection model, fibrin formation of the abscess capsule was mediated by coagulases independently of the FXII-FXI axis (Malachowa et al., 2016). Similarly, a preceding study of *S. pneumoniae* lung infection in mice found that bacteria-triggered coagulation occurred via FXI independently of FXII (Stroo et al., 2017). The discrepancy between the findings of Stroo et al. (2017) and those of the present study is likely due to methodological variations, including differences in infection severity, experimental design, and bacterial strain selection. Specifically, Stroo and colleagues employed a 10-fold lower bacterial inoculation dose (5×10^5 CFU/mouse), which has been shown to induce less TF expression compared with the doses used in the present study (Levi et al., 2003). The relative contribution of FXIIa-versus TF-mediated thrombin-driven FXI feedback activation depends on TF activity (von dem Borne and Meijers, 1995). Real-time thrombin generation assays have shown that FXI feedback activation plays a pivotal role in coagulation at low TF concentrations, whereas at higher TF levels, coagulation activation becomes predominantly independent of the FXI feedback mechanism (Kravtsov et al., 2009). This renders FXI feedback activation particularly relevant to the experimental design of Stroo and colleagues. In a low-grade *E. coli* LPS-induced endotoxemia model in humans, FXI was consistently activated by thrombin, independently of FXIIa (Minnema et al., 1998). Furthermore, Stroo et al. (2017) used a *S. pneumoniae* serotype 2 (D39), and the present study employed a serotype 3 strain (Xen10). Because capsule serotypes influence numerous aspects of pneumococcal pathogenesis, e.g., resistance to phagocytosis, survival during infection, colonization, invasiveness, dissemination, and overall disease progression (Geno et al., 2015; Yother, 2011), direct comparisons between different serotypes are challenging. Indeed, in the present study, the majority of *F12*^{-/-} mice succumbed to infection within four days (Fig. 1), whereas animals challenged with lower doses of a different pneumococcus capsule serotype survived beyond 10 days (Stroo et al., 2017).

The mouse models (Fig. 5) and ex vivo plasma (Fig. 4) data indicate that fibrin produced via the polyP-FXII-FXI pathway drive fibrous abscess capsule formation; in contrast, the addition of FXII (physiological levels; 400 nM) did not affect the growth of *S. aureus* or *S. pneumoniae* in culture. Furthermore, neutrophil extracellular traps components, host defense cells, antimicrobial peptides, and FXIIa-produced bradykinin contribute to bacterial entrapping (Bochenska et al., 2015; Oehmcke et al., 2009). To dissect roles of fibrin depositions versus other pathways transgenic mice with nonpolymerizable fibrin (Hur et al., 2024) or analysis of cohorts of individuals with severe FXII deficiency (e.g., <1%) or patients on FXII(a)/FXI(a) inhibitors may provide valuable insights in future studies.

Fibrin helps the host to cope with infection (Mullarky et al., 2005; Prasad et al., 2015; Sun et al., 2004, 2009). Consistently, mice with a factor V Leiden mutation (a prothrombotic risk factor) are protected from bacterial sepsis. Conversely, defective coagulation in a hemophilia A mouse model increases sepsis-induced mortality (Kerschen et al., 2015). In synergy with plasma factors, neutrophils induce coagulation by exposing neutrophil extracellular traps and inactivating the anticoagulant tissue factor pathway inhibitor (TFPI) (Massberg et al., 2010). TFPI-mediated amplification of TF-driven extrinsic coagulation activity interferes with extravasation of *E. coli* strain XA90 (Massberg et al., 2010), whereas this prothrombotic mechanism appears not to be sufficient to combat *S. aureus* and pneumococci in the absence of FXII, despite the substantial recruitment of leukocyte to the abscess wall (Fig. 4).

PKa liberates bradykinin from high molecular weight kininogen and amplifies FXII activation (Kearney et al., 2024). ASO-mediated knockdown of kininogen gene expression attenuates inflammatory reactions, bacterial dissemination, and growth in multiple organs in a *Streptococcus pyogenes* mouse sepsis model. Depletion of kininogen in mice was associated with a partial PK deficiency, impeded streptococcal spreading, and reduced inflammatory reactions (Köhler et al., 2020). Consistently, the small molecule D-Pro-Phe-Arg chloromethyl ketone (PCK that inhibits PKa>>FXIIa); (Tans et al., 1987) interferes with *Salmonella typhimurium*-triggered contact system activation in lethal experimental sepsis (Persson et al., 2000). In contrast, in our *S. aureus* skin infection model, a complete deficiency in PK augmented local bacterial growth and dissemination. Together, the data may reflect fundamental differences upon residual PKa activities in the knockdown and pharmacologic models that are absent in gene knockout mice or bacterial strain-specific differences in their procoagulant and fibrinolytic activities. It is recommended that subsequent studies utilize a range of pharmacological agents that target the polyP/FXII/FXI/PK pathway (Chan and Weitz, 2023; Mailer et al., 2022; Vappala et al., 2024) to analyze the effects of complete pathway inhibition, as observed in the gene-knockout mouse lines employed in this study, in comparison to transient interference with residual activity on infection severity and pathogen dissemination.

Based on potent thromboprotection while sparing hemostasis observed in experimental thrombosis models in mice and large animals, the polyP-FXII-FXI axis has emerged as a novel target for “safe anticoagulants” (Fredenburgh et al., 2017). Available

X-ray structure and epidemiological data have facilitated development of FXI-blocking agents, including neutralizing antibodies, ASO/small interfering RNAs, and small molecule inhibitors (reviewed by Bentounes et al. [2023]; Fredenburgh and Weitz [2023]; Gailani and Gruber [2024]). Initially, ASO-mediated inhibition of *FII* expression in humans has been shown to provide protection against DVT (Büller et al., 2015). Currently, many novel “safe” anticoagulants that selectively interfere with FXI/FXIa (milvexian, asundexian, abelacimab, IONS fesomersen, REGN-9933) (Verstraete et al., 2024) are in phase 2 and 3 clinical trials for the prophylaxis of atrial fibrillation, DVT, or secondary stroke. These treatments are close to entering clinical practice with far-reaching medical and economic implications for millions of patients worldwide (Chan and Weitz, 2023; Cohen and Ageno, 2022; Fredenburgh and Weitz, 2023; Kluge et al., 2022; Piccini et al., 2025). In addition, long-term pharmacologic neutralization of FXIIa (garadacimab) (Cohn and Renné, 2024) is emerging as prophylactic therapy for hereditary angioedema, a bradykinin-mediated swelling disease (Craig et al., 2023). If the role of FXII-FXI-driven coagulation in bacterial infections translates to humans, pharmacologic interference with FXII(a) and FXI(a) might increase risk of bacterial infection severity and pathogen dissemination leading to sepsis in treated patients, which should be monitored cautiously.

Materials and methods

Bacteria strains and growth conditions

Bioluminescent *S. aureus* strain Xen29 and *S. pneumoniae* strain Xen10 are genetically engineered isolates of their parental strains *S. aureus* ATCC 12600 and *S. pneumoniae* A66.1 (NCTC 7978) that express a modified *Photobacterium luminescens* lux operon (Francis et al., 2001; Kadurugamuwa et al., 2003). Both strains are capable of producing both the luciferase enzyme and its substrate, thereby constitutively emitting a bioluminescent signal when the organisms are metabolically active. The strains were obtained commercially from Xenogen (Caliper Life Science) and have a kanamycin resistance plasmid selection marker. *S. aureus* was cultured in lysogeny broth (LB) medium and *S. pneumoniae* in Todd-Hewitt medium supplemented with 0.5% yeast extract. Cultures were grown to OD₆₀₀ ~0.6 (*S. aureus*) or OD₆₀₀ ~0.4 (*S. pneumoniae*) and washed three times with either sterile saline or sterile PBS/1% FCS, respectively.

Mice

All animal care and experimental procedures complied with the 3R Principles of Laboratory and Animal Care established by the National Society for Medical Research, were conducted in compliance with local authorities, and were approved by Institutional Review Boards, including the Bezirksregierung of Unterfranken (54-2531.01-17/06; Würzburg; *S. pneumoniae* lung infections), Regierung of Oberbayern (55.2-1-54-2531-8-07; Munich; *S. pneumoniae* lung infections), and Stockholm's Norra Djurförsöksetiska Nämnd (N427/10, N246/13, N129/11, N57/14; *S. aureus* skin infection). *F12*^{-/-} (Pauer et al., 2004), *FII*^{-/-} (Gailani et al., 1997), *Klk1*^{-/-} (Sala-Cunill et al., 2015) mice were backcrossed for >10 generations to the C57Bl/6J background, as

previously described. *Fl2*^{-/-} and *Fli*^{-/-} mice were bred to generate *Fl2*^{-/-}/*Fli*^{-/-} mice. These animals were crossed to generate *Fl2*^{-/-}/*Fli*^{-/-} double-deficient mice with the expected Mendelian ratio. Western blotting confirmed absence of FXII and FXI in *Fl2*^{-/-}/*Fli*^{-/-} mice. Progenies were genotyped by using PCR. All experimental animals used in these studies were sex- and age-matched (both male and female). Age- and sex-matched WT control mice were purchased from Charles River (Wiga).

Blood collection

Human plasma was obtained from healthy informed volunteers at the Karolinska University Hospital, approved by the Stockholm ethical committee (Regionala Etikprövningsnämnden). Peripheral venous blood was collected into 3.2% trisodium citrate (9:1 blood-to-citrate ratio). The first 10 ml of sample was discarded. Platelet-poor plasma was prepared by two consecutive centrifugation steps at $3,000 \times g$ for 10 min each. Plasma from individuals with inherited FXII and FXI deficiency was obtained from George King Bio-Medical, Inc. Factor levels were below the western blot detection limit. For blood collection, mice were anesthetized by intraperitoneal injection of 2,2,2-tribromoethanol and 2-methyl-2-butanol prior to being subjected to retro-orbital blood sampling. Murine blood was collected into 3.8% trisodium citrate.

Thrombus formation under flow

Thrombus formation under flow was analyzed as previously described (Larsson et al., 2014) with some minor modifications. Briefly, coverslips were coated with *S. aureus* (1×10^6 CFU/cm²) and blocked with HEPES buffer (136 mM NaCl, 2.7 mM KCl, 0.42 mM NaH₂PO₄, 5 mM HEPES, 2 mM MgCl₂, and 1% BSA, pH 7.4) for 30 min. Coverslips were placed onto a transparent, 50- μ m deep parallel-plate flow chamber (Maastricht Instruments BV), which was pre-rinsed with BSA-containing buffer. Chambers were co-infused with citrate-anticoagulated blood and isotonic CaCl₂/MgCl₂ solution (10:1 ratio) using pulse-free pumps, resulting in free Ca²⁺ and Mg²⁺ concentrations of ≈ 2 mM each. In some cases, blood samples were spiked with PPX Δ 12 (500 μ g ml⁻¹). After 7 min of flow (shear rates of 100 s⁻¹ for venous flow conditions), flow chambers were rinsed with HEPES buffer (pH 7.4) containing 2 mM CaCl₂. Phase-contrast images were recorded with an ORCA-Flash 2.8 CMOS camera (Hamamatsu) and Nikon Eclipse Ti microscope equipped with a $\times 20$ objective. The surface area covered by thrombi was calculated in each image using ImageJ 4.0 software.

Preparation of *S. aureus* for skin inoculation and cutaneous infection

A single colony of the *S. aureus* strain Xen29 was used to inoculate LB medium overnight at 37°C. Overnight cultures were diluted 1:50 into fresh LB medium, grown to the mid-logarithmic phase (OD₆₀₀ ~ 0.6), washed three times, and were resuspended in sterile pharmacy-grade saline (0.9%) at the indicated concentration. CFUs per milliliter were verified by colony counts of serial dilutions plated on LB agar. In the cutaneous infection model, the skin of mice was shaved on the back. Mice were anesthetized using 5% isoflurane, and the back skin was

inoculated subcutaneously with *S. aureus* (1.0×10^9 CFU) in 100 μ l sterile saline (0.9%). Measurement of total lesion size was measured manually using a millimeter ruler. Mice were euthanized at day 5 after infection. For histological analysis, mice were subcutaneously inoculated with 3.0×10^6 CFU, and abscesses were collected 30 h after infection.

S. pneumoniae mouse pneumonia model

Intranasal infections with bioluminescent *S. pneumoniae* and monitoring of pneumococcal growth and dissemination in real-time in mice were performed as described previously (Saleh et al., 2014).

Quantification of bacteria by in vivo bioluminescence

Mice were anesthetized using isoflurane. In vivo bioluminescence imaging was performed using the Xenogen IVIS imaging system (Caliper Life Sciences). Total photon emission of each mouse was quantified with the Living Image software package (Caliper Life Sciences) as previously described (Saleh et al., 2013). Bioluminescence intensities are presented on a pseudocolor scale superimposed on a grayscale photograph. Data were quantified as total flux (photons/sec) within the region of interest.

Bacterial burden and microscopic analysis of tissues

At selected time points after infection, mice were anesthetized by intraperitoneal injection of 2,2,2-tribromoethanol and 2-methyl-2-butanol, and organs were harvested for analyses. The organs were excised and homogenized in ice-cold PBS. Aliquots were serially diluted, plated on LB agar plates and incubated for determining CFU. In addition, abscesses of mice inoculated with 3×10^6 CFU *S. aureus* were fixed in 4% PFA for 48 h at room temperature, embedded in paraffin and thin-sectioned. Sections were either stained with H&E or analyzed histologically for fibrin presence. For fibrin detection, sections were incubated in antigen retrieval buffer (pH 6.2; Biocare Medical) and heated in a 2100 Antigen Retriever (Aptum Biologics Ltd.) for 20 min. Endogenous peroxidases were blocked by incubation in 3% hydrogen peroxide for 20 min. Nonspecific-binding sites in murine tissue sections were blocked using blocking serum provided in the mouse on mouse staining kit (Vector Laboratories). Sections were incubated with 4.7 μ g/ml 59D8 antibody (Kleinschnitz et al., 2006; Renné et al., 2005; von Brühl et al., 2012) in the presence of 1% BSA and 0.01% Tween for 1 h at room temperature. Fibrin was detected using the mouse on mouse staining kit (Vector Laboratories) using 3, 3'-diaminobenzidine as a substrate. Slides were briefly counterstained in Mayer's hematoxylin (Biocare Medical) and photographed on a NIKON Eclipse E600 microscope. Measurement of fibrin deposition/abscess was made by analyzing digital photographs using ImageJ software (Version 2.0). Leukocytes and bacteria per visual field were counted at 40 $\times$ magnification from 6 high-power fields (hpf) of H&E-stained sections.

PolyP isolation and detection

PolyP was extracted from *S. aureus* as previously described (Nickel et al., 2016) with the following modification: Bacteria

were lysed with 100 µg/ml lysostaphin in 20 mM Tris (pH 7.4) in the presence of a phosphatase inhibitor cocktail (Sigma-Aldrich) for 15 min at 37°C before adding sulfuric acid (0.3 M) and sodium chloride (3.5 M), and DNA was digested with 100 µg/ml DNaseI (Sigma-Aldrich) in the presence of 3.5 mM MgCl₂ for 1 h at 37°C before proteinase K (750 µg/ml) digestion for an additional hour. The final polyP preparation was eluted in 20 mM Tris (pH 7.4). PolyP was separated by PAGE using 10% polyacrylamide tris-borate-EDTA (TBE)-urea (7 M) gels and stained using DAPI-negative staining as previously described (Smith and Morrissey, 2007).

Real-time thrombin generation analysis

Thrombin formation in real-time was analyzed with the calibrated automated thrombography method using a Fluorocan Ascent fluorometer (Thermo Fisher Scientific) equipped with a dispenser (Thromboscope BV) as previously described (Nickel et al., 2015). In brief, synthetic (P30; Israel Chemicals Ltd.) or bacterial polyP was incubated with buffer (Tris 20 mM, pH 7.4), PPX, or PPX_Δ12 for 30 min at 37°C (Labberton et al., 2016). Samples were then added to 80 µl platelet-poor plasma. Thrombin generation was initiated by adding 2.5 mM fluorogenic substrate (ZGGR-AMC; Thromboscope BV), and all experiments were run in triplicate. Thrombin formation was quantified using the Thromboscope software package (Version 3.0.0.29).

Statistical methods

Normal distribution was determined by a quantile–quantile plot, and data were analyzed by unpaired two-tailed Student's *t* test or, in the case of multiple comparisons, one-way ANOVA followed by post hoc analysis using Tukey's multiple comparisons test. Prism 8.0 (GraphPad) was used for analysis, and values of *P* < 0.05 were considered statistically significant. Data are expressed as mean values ± SD, unless indicated otherwise.

Data availability

Data are available in the article itself and its supplementary materials. Additional information will be provided upon request from the corresponding author via email: thomas@renne.net.

Acknowledgments

We are grateful to Dr. Chris Oschatz for her assistance with the lung infection experiments and Dr. Jörg Hacker for supporting the start of the study. Parts of the work were performed at the Julius-Maximilians-Universität Würzburg, Würzburg; the Ludwig Maximilians University, Munich; and Karolinska Institutet, Stockholm. We are also grateful for the support of the animal facilities and coworkers.

This work was supported in part by grants from Vetenskapsrådet (K2013-65X-21462-04-5), German Research Foundation (DFG, SFB877, TP A11 and SFB841, TP B8), and a European Research Council grant (ERC-StG-2012-311575_F-12) to T. Renné and the DFG SFB479, TP A7 to S. Hammerschmidt. Additionally, the study was supported by the National Institutes of Health R01 19HL137695, Merit Review Award by the U.S. Veterans Administration and the Oscar D. Ratnoff Endowed

Professorship at Case Western Reserve University (to E.X. Stavrou). The contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH, the U.S. Department of Veterans Affairs, or the United States Government. S. Konrath acknowledges the Society of Thrombosis and Hemostasis Research (GTH) for a GTH Early Career Research Grant. Open access funding provided by Irish Research eLibrary.

Author contributions: K.F. Nickel: investigation, validation, and writing—review and editing. A. Jämsä: investigation, resources, and writing—review and editing. S. Konrath: writing—review and editing. P. Papareddy: visualization. L.M. Butler: formal analysis, investigation, and writing—review and editing. E.X. Stavrou: funding acquisition, methodology, and writing—review and editing. M. Frye: writing—review and editing. M. Gelderblom: formal analysis. B. Nieswandt: conceptualization and writing—review and editing. S. Hammerschmidt: funding acquisition, investigation, methodology, and writing—review and editing. H. Herwald: conceptualization, formal analysis, and writing—original draft, review, and editing. T. Renné: conceptualization, data curation, funding acquisition, project administration, resources, supervision, validation, visualization, and writing—original draft, review, and editing.

Disclosures: K.F. Nickel reported being a current employee at Swedish Orphan Biovitrum GmbH. T. Renné reported patent application number: WO2006066878A1 (Renné, T. & Nieswandt, B., 2005, Targeting Factor XII for Prevention of Thrombus Formation and/or Stabilization.). No other disclosures were reported.

Submitted: 7 January 2025

Revised: 25 March 2025

Accepted: 27 March 2025

References

- Bentounes, N.K., S. Melicene, A.C. Martin, D.M. Smadja, and N. Gendron. 2023. Development of new anticoagulant in 2023: Prime time for anti-factor XI and XIa inhibitors. *J. Med. Vasc.* 48:69–80. <https://doi.org/10.1016/j.jdmv.2023.04.002>
- Bergmann, S., and S. Hammerschmidt. 2007. Fibrinolysis and host response in bacterial infections. *Thromb. Haemost.* 98:512–520. <https://doi.org/10.1160/TH07-02-0117>
- Bochenska, O., M. Rapala-Kozik, N. Wolak, W. Kamysz, D. Grzywacz, W. Aoki, M. Ueda, and A. Kozik. 2015. Inactivation of human kininogen-derived antimicrobial peptides by secreted aspartic proteases produced by the pathogenic yeast *Candida albicans*. *Biol. Chem.* 396:1369–1375. <https://doi.org/10.1515/hsz-2015-0167>
- Bowlin, M.Q., and M.J. Gray. 2021. Inorganic polyphosphate in host and microbe biology. *Trends Microbiol.* 29:1013–1023. <https://doi.org/10.1016/j.tim.2021.02.002>
- Büller, H.R., C. Bethune, S. Bhanot, D. Gailani, B.P. Monia, G.E. Raskob, A. Segers, P. Verhamme, J.I. Weitz, and FXI-ASO TKA Investigators. 2015. Factor XI antisense oligonucleotide for prevention of venous thrombosis. *N. Engl. J. Med.* 372:232–240. <https://doi.org/10.1056/NEJMoa1405760>
- Chan, N.C., and J.I. Weitz. 2023. New therapeutic targets for the prevention and treatment of venous thromboembolism with a focus on factor XI inhibitors. *Arterioscler. Thromb. Vasc. Biol.* 43:1755–1763. <https://doi.org/10.1161/ATVBAHA.123.318781>

- Cheng, A.G., A.C. DeDent, O. Schneewind, and D. Missiakas. 2011. A play in four acts: Staphylococcus aureus abscess formation. *Trends Microbiol.* 19: 225–232. <https://doi.org/10.1016/j.tim.2011.01.007>
- Choi, S.H., S.A. Smith, and J.H. Morrissey. 2011. Polyphosphate is a cofactor for the activation of factor XI by thrombin. *Blood.* 118:6963–6970. <https://doi.org/10.1182/blood-2011-07-368811>
- Cohen, O., and W. Ageno. 2022. Coming soon to a pharmacy near you? FXI and FXII inhibitors to prevent or treat thromboembolism. *Hematology (Am. Soc. Hematol. Educ. Program).* 2022:495–505. <https://doi.org/10.1182/hematology.2022000386>
- Cohn, D.M., and T. Renné. 2024. Targeting factor XIIa for therapeutic interference with hereditary angioedema. *J. Intern. Med.* 296:311–326. <https://doi.org/10.1111/joim.20008>
- Craig, T.J., A. Reshef, H.H. Li, J.S. Jacobs, J.A. Bernstein, H. Farkas, W.H. Yang, E.S.G. Stroes, I. Ohsawa, R. Tachdjian, et al. 2023. Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): A global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet.* 401:1079–1090. [https://doi.org/10.1016/S0140-6736\(23\)00350-1](https://doi.org/10.1016/S0140-6736(23)00350-1)
- Deinema, M.H., M. van Loosdrecht, and A. Scholten. 1985. Some physiological characteristics of Acinetobacter spp. accumulating large amounts of phosphate. *Water Sci. Technol.* 17:119–125. <https://doi.org/10.2166/wst.1985.0226>
- Duan, C., Y. Wang, Q. Wang, J. Li, J. Xie, S. Liu, J. Yang, Y. Huang, W. Zhao, and W. Yin. 2023. Gram-negative bacterial infection causes aggravated innate immune response in sepsis: Studies from clinical samples and cellular models. *Biochem. Biophys. Res. Commun.* 650:137–144. <https://doi.org/10.1016/j.bbrc.2023.01.048>
- Francis, K.P., J. Yu, C. Bellingier-Kawahara, D. Joh, M.J. Hawkinson, G. Xiao, T.F. Purchio, M.G. Caparon, M. Lipsitch, and P.R. Contag. 2001. Visualizing pneumococcal infections in the lungs of live mice using bioluminescent Streptococcus pneumoniae transformed with a novel gram-positive lux transposon. *Infect. Immun.* 69:3350–3358. <https://doi.org/10.1128/IAI.69.5.3350-3358.2001>
- Fredenburgh, J.C., P.L. Gross, and J.I. Weitz. 2017. Emerging anticoagulant strategies. *Blood.* 129:147–154. <https://doi.org/10.1182/blood-2016-09-692996>
- Fredenburgh, J.C., and J.I. Weitz. 2023. News at XI: Moving beyond factor Xa inhibitors. *J. Thromb. Haemost.* 21:1692–1702. <https://doi.org/10.1016/j.jtha.2023.04.021>
- Friedrich, R., P. Panizzi, P. Fuentes-Prior, K. Richter, I. Verhamme, P.J. Anderson, S. Kawabata, R. Huber, W. Bode, and P.E. Bock. 2003. Staphylocoagulase is a prototype for the mechanism of cofactor-induced zymogen activation. *Nature.* 425:535–539. <https://doi.org/10.1038/nature01962>
- Gailani, D., and A. Gruber. 2024. Targeting factor XI and factor XIa to prevent thrombosis. *Blood.* 143:1465–1475. <https://doi.org/10.1182/blood.2023020722>
- Gailani, D., N.M. Lasky, and G.J. Broze Jr. 1997. A murine model of factor XI deficiency. *Blood Coagul. Fibrinolysis.* 8:134–144. <https://doi.org/10.1097/00001721-199703000-00008>
- Geno, K.A., G.L. Gilbert, J.Y. Song, I.C. Skovsted, K.P. Klugman, C. Jones, H.B. Konradsen, and M.H. Nahm. 2015. Pneumococcal capsules and their types: Past, present, and future. *Clin. Microbiol. Rev.* 28:871–899. <https://doi.org/10.1128/CMR.00024-15>
- Grover, S.P., T.M. Olson, B.C. Cooley, and N. Mackman. 2020. Model-dependent contributions of FXII and FXI to venous thrombosis in mice. *J. Thromb. Haemost.* 18:2899–2909. <https://doi.org/10.1111/jth.15037>
- Herwald, H., M. Mörgelin, A. Olsén, M. Rhen, B. Dahlbäck, W. Müller-Esterl, and L. Björck. 1998. Activation of the contact-phase system on bacterial surfaces—a clue to serious complications in infectious diseases. *Nat. Med.* 4:298–302. <https://doi.org/10.1038/nm0398-298>
- Howden, B.P., S.G. Giulieri, T. Wong Fok Lung, S.L. Baines, L.K. Sharkey, J.Y.H. Lee, A. Hachani, I.R. Monk, and T.P. Stinear. 2023. Staphylococcus aureus host interactions and adaptation. *Nat. Rev. Microbiol.* 21: 380–395. <https://doi.org/10.1038/s41579-023-00852-y>
- Hur, W.S., T. Kawano, J.M.N. Mwiza, D.S. Paul, R.H. Lee, E.G. Clark, E.G. Bouck, A. Dutta, C. Cai, S.R. Baker, et al. 2024. Mice expressing non-polymerizable fibrinogen have reduced arterial and venous thrombosis with preserved hemostasis. *Blood.* 143:105–117. <https://doi.org/10.1182/blood.2023020805>
- Isernring, J., J. Köhler, M. Nakata, M. Frank, C. Jans, P. Renault, C. Danne, S. Dramsi, B. Kreikemeyer, and S. Oehmcke-Hecht. 2018. Streptococcus gallolyticus subsp. gallolyticus endocarditis isolate interferes with coagulation and activates the contact system. *Virulence.* 9:248–261. <https://doi.org/10.1080/21505594.2017.1393600>
- Jansen, P.M., R.A. Pixley, M. Brouwer, I.W. de Jong, A.C. Chang, C.E. Hack, F.B. Taylor Jr., and R.W. Colman. 1996. Inhibition of factor XII in septic baboons attenuates the activation of complement and fibrinolytic systems and reduces the release of interleukin-6 and neutrophil elastase. *Blood.* 87:2337–2344. <https://doi.org/10.1182/blood.V87.6.2337.bloodjournal8762337>
- Kadurugamuwa, J.L., L.V. Sin, J. Yu, K.P. Francis, R. Kimura, T. Purchio, and P.R. Contag. 2003. Rapid direct method for monitoring antibiotics in a mouse model of bacterial biofilm infection. *Antimicrob. Agents Chemother.* 47:3130–3137. <https://doi.org/10.1128/AAC.47.10.3130-3137.2003>
- Kahn, R., H. Herwald, W. Müller-Esterl, R. Schmitt, A.C. Sjögren, L. Truedsson, and D. Karpman. 2002. Contact-system activation in children with vasculitis. *Lancet.* 360:535–541. [https://doi.org/10.1016/S0140-6736\(02\)09743-X](https://doi.org/10.1016/S0140-6736(02)09743-X)
- Kalini, D.V. 2021. Factor XII(a) inhibitors: A review of the patent literature. *Expert Opin. Ther. Pat.* 31:1155–1176. <https://doi.org/10.1080/13543776.2021.1945580>
- Kearney, K.J., H.M.H. Spronk, J. Emsley, N.S. Key, and H. Philippou. 2024. Plasma kallikrein as a forgotten clotting factor. *Semin. Thromb. Hemost.* 50:953–961. <https://doi.org/10.1055/s-0043-57034>
- Kerschen, E., I. Hernandez, M. Zogg, M. Maas, and H. Weiler. 2015. Survival advantage of heterozygous factor V Leiden carriers in murine sepsis. *J. Thromb. Haemost.* 13:1073–1080. <https://doi.org/10.1111/jth.12876>
- Kleinschnitz, C., G. Stoll, M. Bendszus, K. Schuh, H.U. Pauer, P. Burfeind, C. Renné, D. Gailani, B. Nieswandt, and T. Renné. 2006. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. *J. Exp. Med.* 203: 513–518. <https://doi.org/10.1084/jem.20052458>
- Kluge, K.E., I. Seljeflot, H. Arnesen, T. Jensen, S. Halvorsen, and R. Helseth. 2022. Coagulation factors XI and XII as possible targets for anticoagulant therapy. *Thromb. Res.* 214:53–62. <https://doi.org/10.1016/j.thromres.2022.04.013>
- Kobayashi, S.D., N. Malachowa, and F.R. DeLeo. 2015. Pathogenesis of Staphylococcus aureus abscesses. *Am. J. Pathol.* 185:1518–1527. <https://doi.org/10.1016/j.ajpath.2014.11.030>
- Köhler, J., C. Maletzki, D. Koczan, M. Frank, A. Springer, C. Steffen, A.S. Revenko, A.R. MacLeod, S. Mikkat, B. Kreikemeyer, and S. Oehmcke-Hecht. 2020. Kininogen supports inflammation and bacterial spreading during Streptococcus Pyogenes Sepsis. *EBioMedicine.* 58:102908. <https://doi.org/10.1016/j.ebiom.2020.102908>
- Kravtsov, D.V., A. Matafonov, E.I. Tucker, M.F. Sun, P.N. Walsh, A. Gruber, and D. Gailani. 2009. Factor XI contributes to thrombin generation in the absence of factor XII. *Blood.* 114:452–458. <https://doi.org/10.1182/blood-2009-02-203604>
- Kulaev, I.S., and V.M. Vagabov. 1983. Polyphosphate metabolism in microorganisms. *Adv. Microb. Physiol.* 24:83–171. [https://doi.org/10.1016/S0065-2911\(08\)60385-9](https://doi.org/10.1016/S0065-2911(08)60385-9)
- Kumble, K.D., and A. Kornberg. 1995. Inorganic polyphosphate in mammalian cells and tissues. *J. Biol. Chem.* 270:5818–5822. <https://doi.org/10.1074/jbc.270.11.5818>
- Labberton, L., E. Kenne, A.T. Long, K.F. Nickel, A. Di Gennaro, R.A. Rigg, J.S. Hernandez, L. Butler, C. Maas, E.X. Stavrou, and T. Renné. 2016. Neutralizing blood-borne polyphosphate in vivo provides safe thromboprotection. *Nat. Commun.* 7:12616. <https://doi.org/10.1038/ncomms12616>
- Lamarche, M.G., B.L. Wanner, S. Crépin, and J. Harel. 2008. The phosphate regulon and bacterial virulence: A regulatory network connecting phosphate homeostasis and pathogenesis. *FEMS Microbiol. Rev.* 32: 461–473. <https://doi.org/10.1111/j.1574-6976.2008.00101.x>
- Larsson, M., V. Rayzman, M.W. Nolte, K.F. Nickel, J. Björkqvist, A. Jämsä, M.P. Hardy, M. Fries, S. Schmidbauer, P. Hedenqvist, et al. 2014. A factor XIIa inhibitory antibody provides thromboprotection in extra-corporeal circulation without increasing bleeding risk. *Sci. Transl. Med.* 6:222ra17. <https://doi.org/10.1126/scitranslmed.3006804>
- Levi, M., T.T. Keller, E. van Gorp, and H. ten Cate. 2003. Infection and inflammation and the coagulation system. *Cardiovasc. Res.* 60:26–39. [https://doi.org/10.1016/S0008-6363\(02\)00857-X](https://doi.org/10.1016/S0008-6363(02)00857-X)
- Liu, J., B.C. Cooley, A. Akinc, J. Butler, and A. Borodovsky. 2020. Knockdown of liver-derived factor XII by GalNAc-siRNA ALN-F12 prevents thrombosis in mice without impacting hemostatic function. *Thromb. Res.* 196:200–205. <https://doi.org/10.1016/j.thromres.2020.08.040>
- Long, A.T., E. Kenne, R. Jung, T.A. Fuchs, and T. Renné. 2016. Contact system revisited: An interface between inflammation, coagulation, and innate

- immunity. *J. Thromb. Haemost.* 14:427–437. <https://doi.org/10.1111/jth.13235>
- Loof, T.G., O. Goldmann, C. Naudin, M. Mörgelin, Y. Neumann, M.C. Pils, S.J. Foster, E. Medina, and H. Herwald. 2015. Staphylococcus aureus-induced clotting of plasma is an immune evasion mechanism for persistence within the fibrin network. *Microbiology (Reading)*. 161:621–627. <https://doi.org/10.1099/mic.0.000019>
- Loof, T.G., M. Mörgelin, L. Johansson, S. Oehmcke, A.I. Olin, G. Dickneite, A. Norrby-Teglund, U. Theopold, and H. Herwald. 2011. Coagulation, an ancestral serine protease cascade, exerts a novel function in early immune defense. *Blood*. 118:2589–2598. <https://doi.org/10.1182/blood-2011-02-337568>
- Lowy, F.D. 1998. Staphylococcus aureus infections. *N. Engl. J. Med.* 339: 520–532. <https://doi.org/10.1056/NEJM199808203390806>
- Mailer, R.K., P. Kuta, and T. Renné. 2022. An update on safe anticoagulation. *Hamostaseologie*. 42:65–72. <https://doi.org/10.1055/a-1717-7958>
- Mailer, R.K.W., L. Hänel, M. Allende, and T. Renné. 2019. Polyphosphate as a target for interference with inflammation and thrombosis. *Front. Med. (Lausanne)*. 6:76. <https://doi.org/10.3389/fmed.2019.00076>
- Malachowa, N., S.D. Kobayashi, K.R. Braughton, and F.R. DeLeo. 2013. Mouse model of Staphylococcus aureus skin infection. *Methods Mol. Biol.* 1031: 109–116. https://doi.org/10.1007/978-1-62703-481-4_14
- Malachowa, N., S.D. Kobayashi, A.R. Porter, K.R. Braughton, D.P. Scott, D.J. Gardner, D.M. Missiakas, O. Schneewind, and F.R. DeLeo. 2016. Contribution of Staphylococcus aureus coagulases and clumping factor A to abscess formation in a rabbit model of skin and soft tissue infection. *PLoS One*. 11:e0158293. <https://doi.org/10.1371/journal.pone.0158293>
- Massberg, S., L. Grahll, M.L. von Bruehl, D. Manukyan, S. Pfeiler, C. Gossmann, V. Brinkmann, M. Lorenz, K. Bidzhikov, A.B. Khandagale, et al. 2010. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. *Nat. Med.* 16:887–896. <https://doi.org/10.1038/nm.2184>
- Mattsson, E., H. Herwald, H. Cramer, K. Persson, U. Sjöbring, and L. Björck. 2001. Staphylococcus aureus induces release of bradykinin in human plasma. *Infect. Immun.* 69:3877–3882. <https://doi.org/10.1128/IAI.69.6.3877-3882.2001>
- McAdow, M., D.M. Missiakas, and O. Schneewind. 2012. Staphylococcus aureus secretes coagulase and von Willebrand factor binding protein to modify the coagulation cascade and establish host infections. *J. Innate Immun.* 4:141–148. <https://doi.org/10.1159/000333447>
- McDevitt, D., T. Nanavaty, K. House-Pompeo, E. Bell, N. Turner, L. McIntire, T. Foster, and M. Höök. 1997. Characterization of the interaction between the Staphylococcus aureus clumping factor (ClfA) and fibrinogen. *Eur. J. Biochem.* 247:416–424. <https://doi.org/10.1111/j.1432-1033.1997.00416.x>
- Meng, Y., Q. Yin, Q. Ma, H. Qin, J. Zhang, B. Zhang, H. Pang, and H. Tian. 2021. FXII regulates the formation of deep vein thrombosis via the PI3K/AKT signaling pathway in mice. *Int. J. Mol. Med.* 47:87. <https://doi.org/10.3892/ijmm.2021.4920>
- Miller, L.S., R.M. O'Connell, M.A. Gutierrez, E.M. Pietras, A. Shahangian, C.E. Gross, A. Thirumala, A.L. Cheung, G. Cheng, and R.L. Modlin. 2006. MyD88 mediates neutrophil recruitment initiated by IL-1R but not TLR2 activation in immunity against Staphylococcus aureus. *Immunity*. 24:79–91. <https://doi.org/10.1016/j.immuni.2005.11.011>
- Minnema, M.C., D. Pajkrt, W.A. Willemin, D. Roem, W.K. Bleeker, M. Levi, S.J. van Deventer, C.E. Hack, and H. ten Cate. 1998. Activation of clotting factor XI without detectable contact activation in experimental human endotoxemia. *Blood*. 92:3294–3301. <https://doi.org/10.1182/blood.V92.9.3294>
- Moreno-Sanchez, D., L. Hernandez-Ruiz, F.A. Ruiz, and R. Docampo. 2012. Polyphosphate is a novel pro-inflammatory regulator of mast cells and is located in acidocalcosomes. *J. Biol. Chem.* 287:28435–28444. <https://doi.org/10.1074/jbc.M112.385823>
- Morrissey, J.H., and S.A. Smith. 2015. Polyphosphate as modulator of hemostasis, thrombosis, and inflammation. *J. Thromb. Haemost.* 13: S92–S97. <https://doi.org/10.1111/jth.12896>
- Mullarky, I.K., F.M. Szaba, K.N. Berggren, M.A. Parent, L.W. Kummer, W. Chen, L.L. Johnson, and S.T. Smiley. 2005. Infection-stimulated fibrin deposition controls hemorrhage and limits hepatic bacterial growth during listeriosis. *Infect. Immun.* 73:3888–3895. <https://doi.org/10.1128/IAI.73.7.3888-3895.2005>
- Müller, F., D. Gailani, and T. Renné. 2011. Factor XI and XII as antithrombotic targets. *Curr. Opin. Hematol.* 18:349–355. <https://doi.org/10.1097/MOH.0b013e3283497e61>
- Müller, F., N.J. Mutch, W.A. Schenk, S.A. Smith, L. Esterl, H.M. Spronk, S. Schmidbauer, W.A. Gahl, J.H. Morrissey, and T. Renné. 2009. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. *Cell*. 139:1143–1156. <https://doi.org/10.1016/j.cell.2009.11.001>
- Müller, W.E.G., H.C. Schröder, and X. Wang. 2019. Inorganic polyphosphates as storage for and generator of metabolic energy in the extracellular matrix. *Chem. Rev.* 119:12337–12374. <https://doi.org/10.1021/acs.chemrev.9b00460>
- Nickel, K.F., L. Labberton, A.T. Long, F. Langer, T.A. Fuchs, E.X. Stavrou, L.M. Butler, and T. Renné. 2016. The polyphosphate/factor XII pathway in cancer-associated thrombosis: Novel perspectives for safe anti-coagulation in patients with malignancies. *Thromb. Res.* 141:S4–S7. [https://doi.org/10.1016/S0049-3848\(16\)30353-X](https://doi.org/10.1016/S0049-3848(16)30353-X)
- Nickel, K.F., and T. Renné. 2012. Crosstalk of the plasma contact system with bacteria. *Thromb. Res.* 130:S78–S83. <https://doi.org/10.1016/j.thromres.2012.08.284>
- Nickel, K.F., G. Ronquist, F. Langer, L. Labberton, T.A. Fuchs, C. Bokemeyer, G. Sauter, M. Graefen, N. Mackman, E.X. Stavrou, et al. 2015. The polyphosphate-factor XII pathway drives coagulation in prostate cancer-associated thrombosis. *Blood*. 126:1379–1389. <https://doi.org/10.1182/blood-2015-01-622811>
- Oehmcke, S., M. Mörgelin, and H. Herwald. 2009. Activation of the human contact system on neutrophil extracellular traps. *J. Innate Immun.* 1: 225–230. <https://doi.org/10.1159/000203700>
- Park, H.S., J. Gu, H.J. You, J.E. Kim, and H.K. Kim. 2016. Factor XII-mediated contact activation related to poor prognosis in disseminated intravascular coagulation. *Thromb. Res.* 138:103–107. <https://doi.org/10.1016/j.thromres.2015.12.011>
- Pauer, H.U., T. Renné, B. Hemmerlein, T. Legler, S. Fritzlar, I. Adham, W. Müller-Esterl, G. Emons, U. Sancken, W. Engel, and P. Burfeind. 2004. Targeted deletion of murine coagulation factor XII gene—a model for contact phase activation in vivo. *Thromb. Haemost.* 92:503–508. <https://doi.org/10.1160/TH04-04-0250>
- Peetermans, M., T. Vanassche, L. Liesenborghs, J. Claes, G. Vande Velde, J. Kwieciński, T. Jin, B. De Geest, M.F. Hoylaerts, R.H. Lijnen, and P. Verhamme. 2014. Plasminogen activation by staphylokinase enhances local spreading of S. aureus in skin infections. *BMC Microbiol.* 14:310. <https://doi.org/10.1186/s12866-014-0310-7>
- Persson, K., M. Mörgelin, L. Lindbom, P. Alm, L. Björck, and H. Herwald. 2000. Severe lung lesions caused by Salmonella are prevented by inhibition of the contact system. *J. Exp. Med.* 192:1415–1424. <https://doi.org/10.1084/jem.192.10.1415>
- Piccini, J.P., M.R. Patel, J. Steffel, K. Ferdinand, I.C. Van Gelder, A.M. Russo, C.S. Ma, S.G. Goodman, J. Oldgren, C. Hammett, et al. 2025. Asundexian versus apixaban in patients with atrial fibrillation. *N. Engl. J. Med.* 392: 23–32. <https://doi.org/10.1056/NEJMoa2407105>
- Pixley, R.A., R. De La Cadena, J.D. Page, N. Kaufman, E.G. Wyshock, A. Chang, F.B. Taylor Jr., and R.W. Colman. 1993. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. *J. Clin. Invest.* 91:61–68. <https://doi.org/10.1172/JCI16201>
- Prasad, J.M., O.V. Gorkun, H. Raghu, S. Thornton, E.S. Mullins, J.S. Palumbo, Y.P. Ko, M. Höök, T. David, S.R. Coughlin, et al. 2015. Mice expressing a mutant form of fibrinogen that cannot support fibrin formation exhibit compromised antimicrobial host defense. *Blood*. 126:2047–2058. <https://doi.org/10.1182/blood-2015-04-639849>
- Puy, C., E.I. Tucker, I.S. Ivanov, D. Gailani, S.A. Smith, J.H. Morrissey, A. Gruber, and O.J. McCarty. 2016. Platelet-derived short-chain polyphosphates enhance the inactivation of tissue factor pathway inhibitor by activated coagulation factor XI. *PLoS One*. 11:e0165172. <https://doi.org/10.1371/journal.pone.0165172>
- Rangarajan, E.S., G. Nadeau, Y. Li, J. Wagner, M.N. Hung, J.D. Schrag, M. Cygler, and A. Matte. 2006. The structure of the exopolyphosphatase (PPX) from Escherichia coli O157:H7 suggests a binding mode for long polyphosphate chains. *J. Mol. Biol.* 359:1249–1260. <https://doi.org/10.1016/j.jmb.2006.04.031>
- Ratnoff, O.D. 1980. A quarter century with Mr. Hageman. *Thromb. Haemost.* 43:95–98. <https://doi.org/10.1055/s-0038-1650025>
- Renné, T., M. Pozgajová, S. Grüner, K. Schuh, H.U. Pauer, P. Burfeind, D. Gailani, and B. Nieswandt. 2005. Defective thrombus formation in mice lacking coagulation factor XII. *J. Exp. Med.* 202:271–281. <https://doi.org/10.1084/jem.20050664>
- Revenko, A.S., D. Gao, J.R. Crosby, G. Bhattacharjee, C. Zhao, C. May, D. Gailani, B.P. Monia, and A.R. MacLeod. 2011. Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. *Blood*. 118:5302–5311. <https://doi.org/10.1182/blood-2011-05-355248>

- Sala-Cunill, A., J. Björkqvist, R. Senter, M. Guilarte, V. Cardona, M. Labrador, K.F. Nickel, L. Butler, O. Luengo, P. Kumar, et al. 2015. Plasma contact system activation drives anaphylaxis in severe mast cell-mediated allergic reactions. *J. Allergy Clin. Immunol.* 135:1031–1043.e6. <https://doi.org/10.1016/j.jaci.2014.07.057>
- Saleh, M., M.R. Abdullah, C. Schulz, T. Kohler, T. Pribyl, I. Jensch, and S. Hammerschmidt. 2014. Following in real time the impact of pneumococcal virulence factors in an acute mouse pneumonia model using bioluminescent bacteria. *J. Vis. Exp.*:e51174. <https://doi.org/10.3791/51174>
- Saleh, M., S.G. Bartual, M.R. Abdullah, I. Jensch, T.M. Asmat, L. Petruschka, T. Pribyl, M. Gellert, C.H. Lillig, H. Antelmann, et al. 2013. Molecular architecture of *Streptococcus pneumoniae* surface thioredoxin-fold lipoproteins crucial for extracellular oxidative stress resistance and maintenance of virulence. *EMBO Mol. Med.* 5:1852–1870. <https://doi.org/10.1002/emmm.201202435>
- Silasi, R., R.S. Keshari, G. Regmi, C. Lupu, C. Georgescu, J.H. Simmons, M. Wallisch, T.C.L. Kohs, J.J. Shatzel, S.R. Olson, et al. 2021. Factor XII plays a pathogenic role in organ failure and death in baboons challenged with *Streptococcus aureus*. *Blood*. 138:178–189. <https://doi.org/10.1182/blood.2020009345>
- Smith, S.A., and J.H. Morrissey. 2007. Sensitive fluorescence detection of polyphosphate in polyacrylamide gels using 4',6-diamidino-2-phenylindol. *Electrophoresis*. 28:3461–3465. <https://doi.org/10.1002/elps.200700041>
- Sriskandan, S., G. Kemball-Cook, D. Moyes, J. Canvin, E. Tuddenham, and J. Cohen. 2000. Contact activation in shock caused by invasive group A *Streptococcus pyogenes*. *Crit. Care Med.* 28:3684–3691. <https://doi.org/10.1097/00003246-200011000-00025>
- Stroo, I., S. Zeerleder, C. Ding, B.M. Luken, J.J.T.H. Roelofs, O.J. de Boer, J.C.M. Meijers, F.J. Castellino, C. van 't Veer, and T. van der Poll. 2017. Coagulation factor XI improves host defence during murine pneumonia-derived sepsis independent of factor XII activation. *Thromb. Haemost.* 117:1601–1614. <https://doi.org/10.1160/TH16-12-0920>
- Sun, H., U. Ringdahl, J.W. Homeister, W.P. Fay, N.C. Engleberg, A.Y. Yang, L.S. Rozek, X. Wang, U. Sjöbring, and D. Ginsburg. 2004. Plasminogen is a critical host pathogenicity factor for group A streptococcal infection. *Science*. 305:1283–1286. <https://doi.org/10.1126/science.1101245>
- Sun, H., X. Wang, J.L. Degen, and D. Ginsburg. 2009. Reduced thrombin generation increases host susceptibility to group A streptococcal infection. *Blood*. 113:1358–1364. <https://doi.org/10.1182/blood-2008-07-170506>
- Tans, G., T. Janssen-Claessen, J. Rosing, and J.H. Griffin. 1987. Studies on the effect of serine protease inhibitors on activated contact factors. Application in amidolytic assays for factor XIIa, plasma kallikrein and factor XIa. *Eur. J. Biochem.* 164:637–642. <https://doi.org/10.1111/j.1432-1033.1987.tb11174.x>
- Tanzer, J.M., and M.I. Krichevsky. 1970. Polyphosphate formation by caries-conducive streptococcus SL-I. *Biochim. Biophys. Acta*. 215:368–376. [https://doi.org/10.1016/0304-4165\(70\)90036-X](https://doi.org/10.1016/0304-4165(70)90036-X)
- Townsend, N., D. Kazakiewicz, F. Lucy Wright, A. Timmis, R. Huculeci, A. Torbica, C.P. Gale, S. Achenbach, F. Weidinger, and P. Vardas. 2022. Epidemiology of cardiovascular disease in Europe. *Nat. Rev. Cardiol.* 19: 133–143. <https://doi.org/10.1038/s41569-021-00607-3>
- Tucker, E.I., N.G. Verbout, P.Y. Leung, S. Hurst, O.J. McCarty, D. Gailani, and A. Gruber. 2012. Inhibition of factor XI activation attenuates inflammation and coagulopathy while improving the survival of mouse polymicrobial sepsis. *Blood*. 119:4762–4768. <https://doi.org/10.1182/blood-2011-10-386185>
- Umei, N., S. Shin, A. Lai, J. Miller, K. Roberts, D. Strelkova, N. Chaudhary, S. Ichiba, A. Sakamoto, K. Whitehead, and K. Cook. 2023. Factor XII silencing using siRNA prevents Thrombus Formation in a rat model of extracorporeal Life support. *ASAIO J.* 69:527–532. <https://doi.org/10.1097/MAT.0000000000001876>
- van der Poll, T., and H. Herwald. 2014. The coagulation system and its function in early immune defense. *Thromb. Haemost.* 112:640–648. <https://doi.org/10.1160/TH14-01-0053>
- Vappala, S., S.A. Smith, J.N. Kizhakkedathu, and J.H. Morrissey. 2024. Inhibitors of polyphosphate and neutrophil extracellular traps. *Semin. Thromb. Hemost.* 50:970–977. <https://doi.org/10.1055/s-0043-1768936>
- Verhoef, J.J., A.D. Barendrecht, K.F. Nickel, K. Dijkshoorn, E. Kenne, L. Labberton, O.J. McCarty, R. Schiffelers, H.F. Heijnen, A.P. Hendrickx, et al. 2017. Polyphosphate nanoparticles on the platelet surface trigger contact system activation. *Blood*. 129:1707–1717. <https://doi.org/10.1182/blood-2016-08-734988>
- Verstraete, A., M.M. Engelen, C. Van Edom, T. Vanassche, and P. Verhamme. 2024. Reshaping anticoagulation: Factor XI inhibition in thrombosis management. *Hamostaseologie*. 44:49–58. <https://doi.org/10.1055/s-2202-8620>
- von Brühl, M.L., K. Stark, A. Steinhart, S. Chandraratne, I. Konrad, M. Lorenz, A. Khandoga, A. Tirmiceriu, R. Coletti, M. Köllnberger, et al. 2012. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. *J. Exp. Med.* 209:819–835. <https://doi.org/10.1084/jem.20112322>
- von dem Borne, P.A., J.C. Meijers, and B.N. Bouma. 1995. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. *Blood*. 86: 3035–3042. <https://doi.org/10.1182/blood.V86.8.3035.3035>
- Wang, H.W., N. Tedla, A.R. Lloyd, D. Wakefield, and P.H. McNeil. 1998. Mast cell activation and migration to lymph nodes during induction of an immune response in mice. *J. Clin. Invest.* 102:1617–1626. <https://doi.org/10.1172/JCI3704>
- Wilbs, J., X.D. Kong, S.J. Middendorp, R. Prince, A. Cooke, C.T. Demarest, M.M. Abdelhazef, K. Roberts, N. Umei, P. Gonschorek, et al. 2020. Cyclic peptide FXII inhibitor provides safe anticoagulation in a thrombosis model and in artificial lungs. *Nat. Commun.* 11:3890. <https://doi.org/10.1038/s41467-020-17648-w>
- Wuillemin, W.A., K. Fijnvandraat, B.H. Derkx, M. Peters, W. Vreede, H. ten Cate, and C.E. Hack. 1995. Activation of the intrinsic pathway of coagulation in children with meningococcal septic shock. *Thromb. Haemost.* 74:1436–1441. <https://doi.org/10.1055/s-0038-1649961>
- Xu, P., Y. Zhang, J. Guo, H. Li, S. Konrath, P. Zhou, L. Cai, H. Rao, H. Chen, J. Lin, et al. 2024. A single-domain antibody targeting factor XII inhibits both thrombosis and inflammation. *Nat. Commun.* 15:7898. <https://doi.org/10.1038/s41467-024-51745-4>
- Yau, J.W., P. Liao, J.C. Fredenburgh, A.R. Stafford, A.S. Revenko, B.P. Monia, and J.I. Weitz. 2014. Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. *Blood*. 123:2102–2107. <https://doi.org/10.1182/blood-2013-12-540872>
- Yother, J. 2011. Capsules of *Streptococcus pneumoniae* and other bacteria: Paradigms for polysaccharide biosynthesis and regulation. *Annu. Rev. Microbiol.* 65:563–581. <https://doi.org/10.1146/annurev.micro.62.081307.162944>
- Zilberman-Rudenko, J., S.E. Reitsma, C. Puy, R.A. Rigg, S.A. Smith, E.I. Tucker, R. Silasi, A. Merkulova, K.R. McCrae, C. Maas, et al. 2018. Factor XII activation promotes platelet consumption in the presence of bacterial-type long-chain polyphosphate in vitro and in vivo. *Arterioscler. Thromb. Vasc. Biol.* 38:1748–1760. <https://doi.org/10.1161/ATVBAHA.118.311193>